Pharmaceutical - pembrolizumab

Filter

Current filters:

pembrolizumab

Popular Filters

Merck & Co’s melanoma drug Keytruda becomes first FDA-approved anti-PD-1 therapy

Merck & Co’s melanoma drug Keytruda becomes first FDA-approved anti-PD-1 therapy

05-09-2014

The US Food and Drug Administration has granted accelerated approval for pharma giant Merck & Co’s…

KeytrudaMerck & CoOncologypembrolizumabPharmaceuticalRegulationUSA

Pfizer and Merck to explore potential of Xalkori/pembrolizumab combo

Pfizer and Merck to explore potential of Xalkori/pembrolizumab combo

26-08-2014

US pharma giants Pfizer and Merck & Co have inked an agreement to explore the therapeutic potential of…

Merck & CoOncologypembrolizumabPfizerPharmaceuticalResearchXalkori

EMA accepts Merck’s pembrolizumab MAA for review

EMA accepts Merck’s pembrolizumab MAA for review

01-07-2014

US pharma giant Merck & Co says that the European Medicines Agency has accepted for review a Marketing…

EuropeMerck & CoOncologypembrolizumabPharmaceuticalRegulation

Excitement as Merck releases new data on cancer drug candidate pembrolizumab

Excitement as Merck releases new data on cancer drug candidate pembrolizumab

03-06-2014

The findings released at the 2014 American Society of Clinical Oncology (ASCO) conference in Chicago…

Merck & CoOncologypembrolizumabPharmaceuticalResearch

Back to top